Dhall, A.; Taniyama, D.; Elloumi, F.; Luna, A.; Varma, S.; Kumar, S.; Escobedo, L.; Sun, Y.; Aladjem, M.I.; Redon, C.E.;
et al. Bimodal Genomic Approach Predicting Semaphorin 7A (SEMA7A) as Prognostic Biomarker in Adrenocortical Carcinoma. Cancers 2025, 17, 2078.
https://doi.org/10.3390/cancers17132078
AMA Style
Dhall A, Taniyama D, Elloumi F, Luna A, Varma S, Kumar S, Escobedo L, Sun Y, Aladjem MI, Redon CE,
et al. Bimodal Genomic Approach Predicting Semaphorin 7A (SEMA7A) as Prognostic Biomarker in Adrenocortical Carcinoma. Cancers. 2025; 17(13):2078.
https://doi.org/10.3390/cancers17132078
Chicago/Turabian Style
Dhall, Anjali, Daiki Taniyama, Fathi Elloumi, Augustin Luna, Sudhir Varma, Suresh Kumar, Lauren Escobedo, Yilun Sun, Mirit I. Aladjem, Christophe E. Redon,
and et al. 2025. "Bimodal Genomic Approach Predicting Semaphorin 7A (SEMA7A) as Prognostic Biomarker in Adrenocortical Carcinoma" Cancers 17, no. 13: 2078.
https://doi.org/10.3390/cancers17132078
APA Style
Dhall, A., Taniyama, D., Elloumi, F., Luna, A., Varma, S., Kumar, S., Escobedo, L., Sun, Y., Aladjem, M. I., Redon, C. E., Roper, N., Reinhold, W. C., Del Rivero, J., & Pommier, Y.
(2025). Bimodal Genomic Approach Predicting Semaphorin 7A (SEMA7A) as Prognostic Biomarker in Adrenocortical Carcinoma. Cancers, 17(13), 2078.
https://doi.org/10.3390/cancers17132078
